

Remibrutinib-treated patients with CSU who achieve well-controlled disease activity reach this by week 3 in the majority of patients: Results from REMIX-1/-2 studies

M. Metz, M. Hide, W. Lai, S. Haemmerle, N. Chapman-Rothe, C-E. Ortmann, G. Mosnaim

Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this [LINK](#) to access the publication once it has been presented at the congress

EADV 2025, European Academy of Dermatology and Venereology. (EADV), 17–20 September 2025